Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting

Alkermes plc

today announced that data will be presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 8-12, 2013, related to the company's two most advanced clinical candidates, aripiprazole lauroxil, a long-acting injectable treatment for schizophrenia, and ALKS 5461, a novel oral compound for the treatment of major depressive disorder (MDD). Enrollment in the phase 3 study for aripiprazole lauroxil has been completed, and ALKS 5461 is expected to enter phase 3 clinical trials in 2014. Details for these presentations at the ACNP meeting include: Monday, Dec. 9, 2013, 5:30-7:30 p.m. EST